反应详情

(R/S)-2-Hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)acetic acid (Int-V, 23 mg, 0.053 mmol), thiazol-2-ylmethanamine-HCl (12.05 mg, 0.080 mmol), 4-methylmorpholine (21.57 mg, 0.213 mmol), and HATU (26.4 mg, 0.069 mmol) were added to DMF (1 mL). This was stirred for 1 h before it was purified by prep HPLC (YMC S5 20×100 mm, gradient elution with Method 1—MeOH/water containing 0.1% trifluoroacetic acid as defined above 0% B to 100% B over 10 min, 20 mL/min, 220 nM, product retention=11.8 min) to provide (R/S)-2-hydroxy-2-(4-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1,2,4-oxadiazol-3-yl)phenyl)-N-(thiazol-2-ylmethyl)acetamide (19 mg, 0.033 mmol, 62.3% yield): LCMS=528.2 [M+H]+; 1H NMR (400 MHz, methanol-d4) δ ppm 8.13-8.22 (2 H, m), 7.46-7.78 (9 H, m), 5.22 (1 H, s), 4.67-4.82 (2 H, m); HPLC peak RT=9.5 min (Method A).

1. customwas purified by prep HPLC (YMC S5 20×100 mm, gradient elution with Method 1—MeOH/water containing 0.1% trifluoroacetic acid as defined above 0% B to 100% B over 10 min, 20 mL/min, 220 nM, product retention=11.8 min)